Building Decision-Grade EEG Biomarkers to De-Risk Alzheimer’s & ALS Drug Development

• Using resting-state and auditory EEG biomarkers to detect pharmacodynamic effects and confirm target engagement in early brain disease studies
• Identifying biologically responsive patient subgroups to reduce heterogeneity and improve patient selection strategies
• Applying EEG-based responder identification approaches to support go/no-go decisions and progression into larger Phase 2 and 3 studies
• Exploring the role of neurophysiology biomarkers in advancing precision neuroscience and biomarker-informed trial design

Speakers:

Ernest Pedapati

Professor, UC Department of Psychiatry and Behavioral Neuroscience

Cincinnati Children’s Hospital